Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28377771 | 1.00 | MEN1 (0.39) | MEN1KMT2ATDP1CA2ALDH1A1 | |
| SCHEMBL974251 | 1.00 | MEN1 (0.39) | MEN1KMT2ATDP1CA2ALDH1A1 | |
| SCHEMBL13952077 | 0.98 | MEN1 (0.38) | MEN1KMT2ATDP1CA2 | |
| SCHEMBL11525095 | 0.89 | MEN1 (0.44) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL27751669 | 0.87 | CA2 (0.35) | CA2 | |
| SCHEMBL5445934 | 0.87 | MEN1 (0.46) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL17225877 | 0.86 | TSHR (0.35) | MEN1KMT2ATDP1CA2CYP3A4 | |
| SCHEMBL247006 | 0.84 | — | — | |
| SCHEMBL15593320 | 0.79 | — | — | |
| SCHEMBL8940399 | 0.78 | MEN1 (0.52) | MEN1KMT2ATDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
| EP-1842250-B1 | ELECTRIC CURRENT-PRODUCING DEVICE HAVING A SULFONE-BASED ELECTROLYTE | UNIV ARIZONA (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20110020712-A1 | ELECTRIC CURRENT-PRODUCING DEVICE HAVING SULFONE-BASED ELECTROLYTE | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-7833666-B2 | Electric current-producing device having sulfone-based electrolyte | Arizona Board of Regents for and behalf of Arizona State University (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070298326-A1 | Electric Current-Producing Device Having Sulfone-Based Electrolyte | UNITED STATES DEPARTMENT OF ENERGY | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | MEN1 2078/4885KMT2A 4455/4885TDP1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.